$IRWD
Ironwood Pharmaceuticals Inc

2011 Q3 Form 10-Q Financial Statement

#000110465911062735 Filed on November 09, 2011

View on sec.gov

Income Statement

Concept 2011 Q3 2010 Q4 2010 Q3
Revenue $12.22M $16.80M $9.059M
YoY Change 34.87% 100.0% -40.79%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $10.90M $8.300M $6.500M
YoY Change 67.69% 48.21% 32.65%
% of Gross Profit
Research & Development $22.91M $21.30M $18.74M
YoY Change 22.21% -11.98% 0.76%
% of Gross Profit
Depreciation & Amortization $2.300M $2.000M $1.500M
YoY Change 53.33% 66.67% 50.0%
% of Gross Profit
Operating Expenses $33.83M $29.60M $25.22M
YoY Change 34.13% -0.67% 7.34%
Operating Profit -$21.62M -$16.17M
YoY Change 33.72%
Interest Expense $16.00K $200.0K $81.00K
YoY Change -80.25%
% of Operating Profit
Other Income/Expense, Net $986.0K $1.000M $107.0K
YoY Change 821.5% 42.86%
Pretax Income -$20.63M -$11.70M -$16.06M
YoY Change 28.47% -43.48% 93.47%
Income Tax $3.000K $0.00 -$2.944M
% Of Pretax Income
Net Earnings -$20.60M -$11.70M -$6.747M
YoY Change 205.32% -51.05% -38.1%
Net Earnings / Revenue -168.6% -69.64% -74.48%
Basic Earnings Per Share -$0.21
Diluted Earnings Per Share -$0.21 -$118.7K -$84.78K
COMMON SHARES
Basic Shares Outstanding 100.2M shares 97.93M shares
Diluted Shares Outstanding 100.2M shares 97.93M shares

Balance Sheet

Concept 2011 Q3 2010 Q4 2010 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $175.1M $248.0M $250.8M
YoY Change -30.18% 102.78% 153.59%
Cash & Equivalents $68.82M $44.32M $58.70M
Short-Term Investments $106.3M $203.7M $192.1M
Other Short-Term Assets $2.900M $8.100M $7.400M
YoY Change -60.81% 102.5% -16.85%
Inventory
Prepaid Expenses
Receivables $700.0K $19.00K $5.000M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $178.8M $259.1M $263.3M
YoY Change -32.09% 97.17% 123.51%
LONG-TERM ASSETS
Property, Plant & Equipment $32.90M $34.37M $33.30M
YoY Change -1.2% 57.66% 42.31%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $7.800M $274.0K $8.000M
YoY Change -2.5% -97.02% -4.76%
Total Long-Term Assets $40.70M $42.29M $41.20M
YoY Change -1.21% 35.98% 29.56%
TOTAL ASSETS
Total Short-Term Assets $178.8M $259.1M $263.3M
Total Long-Term Assets $40.70M $42.29M $41.20M
Total Assets $219.5M $301.4M $304.5M
YoY Change -27.91% 85.46% 103.54%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.400M $4.302M $5.900M
YoY Change -59.32% -10.38% -7.81%
Accrued Expenses $16.90M $8.938M $11.90M
YoY Change 42.02% -46.48% 16.67%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $200.0K $200.0K $200.0K
YoY Change 0.0% -81.82% -87.5%
Total Short-Term Liabilities $70.85M $64.43M $55.80M
YoY Change 26.97% 14.23% 9.2%
LONG-TERM LIABILITIES
Long-Term Debt $500.0K $400.0K $400.0K
YoY Change 25.0% -55.56% -80.95%
Other Long-Term Liabilities $35.20M $77.00M $80.20M
YoY Change -56.11% -26.74% -2.67%
Total Long-Term Liabilities $35.70M $77.40M $80.60M
YoY Change -55.71% -26.98% -4.62%
TOTAL LIABILITIES
Total Short-Term Liabilities $70.85M $64.43M $55.80M
Total Long-Term Liabilities $35.70M $77.40M $80.60M
Total Liabilities $106.6M $141.8M $136.5M
YoY Change -21.9% -14.42% -2.15%
SHAREHOLDERS EQUITY
Retained Earnings -$367.5M
YoY Change
Common Stock $527.0M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $112.9M $159.6M $168.1M
YoY Change
Total Liabilities & Shareholders Equity $219.5M $301.4M $304.5M
YoY Change -27.92% 85.46% 103.54%

Cashflow Statement

Concept 2011 Q3 2010 Q4 2010 Q3
OPERATING ACTIVITIES
Net Income -$20.60M -$11.70M -$6.747M
YoY Change 205.32% -51.05% -38.1%
Depreciation, Depletion And Amortization $2.300M $2.000M $1.500M
YoY Change 53.33% 66.67% 50.0%
Cash From Operating Activities -$25.40M -$600.0K -$22.80M
YoY Change 11.4% -105.71% 273.77%
INVESTING ACTIVITIES
Capital Expenditures -$500.0K -$2.100M -$6.500M
YoY Change -92.31% 162.5% 1525.0%
Acquisitions
YoY Change
Other Investing Activities $46.10M -$12.30M $53.20M
YoY Change -13.35% -169.89% -601.89%
Cash From Investing Activities $45.50M -$14.40M $46.70M
YoY Change -2.57% -185.71% -520.72%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 600.0K 800.0K -600.0K
YoY Change -200.0% -94.63% -102.41%
NET CHANGE
Cash From Operating Activities -25.40M -600.0K -22.80M
Cash From Investing Activities 45.50M -14.40M 46.70M
Cash From Financing Activities 600.0K 800.0K -600.0K
Net Change In Cash 20.70M -14.20M 23.30M
YoY Change -11.16% -133.65% 202.6%
FREE CASH FLOW
Cash From Operating Activities -$25.40M -$600.0K -$22.80M
Capital Expenditures -$500.0K -$2.100M -$6.500M
Free Cash Flow -$24.90M $1.500M -$16.30M
YoY Change 52.76% -86.73% 185.96%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2010Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
301365000 USD
CY2010Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
159551000 USD
CY2010Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
1000 USD
CY2010Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-367540000 USD
CY2010Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
526991000 USD
CY2010Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
62383000 USD
CY2010Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
14612000 USD
CY2010Q4 us-gaap Capital Lease Obligations Noncurrent
CapitalLeaseObligationsNoncurrent
393000 USD
CY2010Q4 us-gaap Liabilities Current
LiabilitiesCurrent
64426000 USD
CY2010Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
40050000 USD
CY2010Q4 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
2799000 USD
CY2010Q4 us-gaap Capital Lease Obligations Current
CapitalLeaseObligationsCurrent
197000 USD
CY2010Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
8938000 USD
CY2010Q4 irwd Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
8140000 USD
CY2010Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
4302000 USD
CY2010Q4 us-gaap Assets
Assets
301365000 USD
CY2010Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
274000 USD
CY2010Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
34369000 USD
CY2010Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
7647000 USD
CY2010Q4 us-gaap Assets Current
AssetsCurrent
259075000 USD
CY2010Q4 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
2833000 USD
CY2010Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5320000 USD
CY2010Q4 us-gaap Due From Related Parties Current
DueFromRelatedPartiesCurrent
2876000 USD
CY2010Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
19000 USD
CY2010Q4 us-gaap Available For Sale Securities Current
AvailableForSaleSecuritiesCurrent
203706000 USD
CY2010Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
44321000 USD
CY2011Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
219480000 USD
CY2011Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
112930000 USD
CY2011Q3 us-gaap Liabilities Current
LiabilitiesCurrent
70848000 USD
CY2010Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2011Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2010Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2010Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2011Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2010Q3 us-gaap Interest Expense
InterestExpense
81000 USD
us-gaap Interest Expense
InterestExpense
178000 USD
CY2011Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2010Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
75000000 shares
CY2011Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
75000000 shares
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
15090000 USD
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
1891000 USD
us-gaap Capital Lease Obligations Incurred
CapitalLeaseObligationsIncurred
529000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-2944000 USD
CY2010Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-2944000 USD
us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Noncontrolling Interest
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest
1121000 USD
CY2010Q3 us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Noncontrolling Interest
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest
1523000 USD
us-gaap Profit Loss
ProfitLoss
-40209000 USD
us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
4551000 USD
us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
-44760000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-47704000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
267000 USD
us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
445000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-47971000 USD
us-gaap Operating Expenses
OperatingExpenses
75056000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
18868000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
56188000 USD
CY2010Q3 us-gaap Profit Loss
ProfitLoss
-6747000 USD
CY2010Q3 us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
6367000 USD
CY2010Q3 us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
-13114000 USD
CY2010Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-16058000 USD
CY2010Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
107000 USD
CY2010Q3 us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
188000 USD
CY2010Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-16165000 USD
CY2010Q3 us-gaap Operating Expenses
OperatingExpenses
25224000 USD
CY2010Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6482000 USD
CY2010Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
18742000 USD
us-gaap Revenues
Revenues
27085000 USD
CY2010Q3 us-gaap Revenues
Revenues
9059000 USD
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
86633080 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
86633080 shares
CY2010Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
97925657 shares
CY2010Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
97925657 shares
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
296000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1896000 USD
us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
2348000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-170000 USD
us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
322319000 USD
us-gaap Nature Of Operations
NatureOfOperations
<table style="font-size:10pt; font-family:'Times New Roman',times,serif;"> <tr> <td> <p style="MARGIN: 0in 0in 0pt"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold" size="2">1. Nature of Business</font></b></p> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2">&nbsp;</font></p> <p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2">Ironwood Pharmaceuticals,&nbsp;Inc. (the &#147;Company&#148;) is an entrepreneurial pharmaceutical company that discovers, develops and intends to commercialize differentiated medicines that improve patients&#146; lives. The Company&#146;s lead product candidate is linaclotide, a guanylate cyclase type-C (&#147;GC-C&#148;) agonist being developed for the treatment of patients with irritable bowel syndrome with constipation (&#147;IBS-C&#148;) or chronic constipation (&#147;CC&#148;). The Company and its U.S. collaboration partner, Forest Laboratories,&nbsp;Inc. (&#147;Forest&#148;), announced in August&nbsp;2011 that they submitted a New Drug Application (&#147;NDA&#148;) to the U.S. Food and Drug Administration (&#147;FDA&#148;) for linaclotide. On September&nbsp;29, 2011, the Company and its European partner, Almirall, S.A. (&#147;Almirall&#148;) each announced that Almirall submitted a Market Authorization Application (&#147;MAA&#148;) to the European Medicines Agency (&#147;EMA&#148;) for linaclotide for the treatment of IBS-C. The Company also has a pipeline focused on both research and development of early stage product candidates and preclinical research in multiple therapeutic areas, including gastrointestinal disease, pain and inflammation, respiratory disease and cardiovascular disease.</font></p> <p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2">&nbsp;</font></p> <p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2">Prior to September&nbsp;2010, the Company held a majority ownership interest in Microbia,&nbsp;Inc. (formerly known as Microbia Precision Engineering), a subsidiary formed in September&nbsp;2006. Microbia,&nbsp;Inc. (&#147;Microbia&#148;) engaged in a specialty biochemicals business based on a proprietary strain-development platform. In September&nbsp;2010, the Company sold its interest in Microbia to DSM Holding Company USA,&nbsp;Inc. (&#147;DSM&#148;) (Note 2).</font></p> <p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2">&nbsp;</font></p> <p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2">The Company was incorporated in Delaware on January&nbsp;5, 1998. On April&nbsp;7, 2008, the Company changed its name from Microbia,&nbsp;Inc. to Ironwood Pharmaceuticals,&nbsp;Inc.</font></p> <p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2">&nbsp;</font></p> <p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2">The Company has generated an accumulated deficit as of September&nbsp;30, 2011 of approximately $425.4 million since inception. In February&nbsp;2010, the Company completed its initial public offering of Class&nbsp;A common stock and raised a total of approximately $203.2 million in net proceeds (Note 3).</font></p></td></tr></table>
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2011
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Amendment Flag
AmendmentFlag
false
dei Document Period End Date
DocumentPeriodEndDate
2011-09-30
dei Document Type
DocumentType
10-Q
dei Entity Central Index Key
EntityCentralIndexKey
0001446847
dei Entity Registrant Name
EntityRegistrantName
IRONWOOD PHARMACEUTICALS INC
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-249000 USD
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-895000 USD
irwd Debt And Interest Paid By Purchaser Of Subsidiary
DebtAndInterestPaidByPurchaserOfSubsidiary
1075000 USD
us-gaap Interest Paid
InterestPaid
308000 USD
CY2010Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
58696000 USD
CY2009Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
122306000 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-63610000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
202214000 USD
us-gaap Cash Provided By Used In Financing Activities Discontinued Operations
CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations
-277000 USD
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
202491000 USD
irwd Proceeds From Stock Options Exercised And Essp And Issuance Of Restricted Stock
ProceedsFromStockOptionsExercisedAndESSPAndIssuanceOfRestrictedStock
1215000 USD
us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
203167000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-198571000 USD
us-gaap Cash Provided By Used In Investing Activities Discontinued Operations
CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations
1000 USD
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-198572000 USD
us-gaap Proceeds From Divestiture Of Interest In Consolidated Subsidiaries
ProceedsFromDivestitureOfInterestInConsolidatedSubsidiaries
9500000 USD
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
129337000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-67253000 USD
us-gaap Cash Provided By Used In Operating Activities Discontinued Operations
CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations
-5969000 USD
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-61284000 USD
irwd Increase Decrease In Deferred Rent Payables
IncreaseDecreaseInDeferredRentPayables
7480000 USD
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-26097000 USD
irwd Increase Decrease In Accrued Research And Development Expense
IncreaseDecreaseInAccruedResearchAndDevelopmentExpense
-7073000 USD
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
3011000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
5136000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
4245000 USD

Files In Submission

Name View Source Status
0001104659-11-062735-index-headers.html Edgar Link pending
0001104659-11-062735-index.html Edgar Link pending
0001104659-11-062735.txt Edgar Link pending
0001104659-11-062735-xbrl.zip Edgar Link pending
a11-25863_110q.htm Edgar Link pending
a11-25863_1ex31d1.htm Edgar Link pending
a11-25863_1ex31d2.htm Edgar Link pending
a11-25863_1ex32d1.htm Edgar Link pending
a11-25863_1ex32d2.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
irwd-20110930.xml Edgar Link completed
irwd-20110930.xsd Edgar Link pending
irwd-20110930_cal.xml Edgar Link unprocessable
irwd-20110930_def.xml Edgar Link unprocessable
irwd-20110930_lab.xml Edgar Link unprocessable
irwd-20110930_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending